PerformSpecialty ^®, an independent company, will facilitate delivery of the drug Synagis (palivizumab) through Independence’s Direct Ship Drug Program for the upcoming respiratory syncytial virus (RSV) season, which runs from November 2019 through March 2020.

As a reminder, it is mandatory for all participating providers to obtain Synagis for their patients who are Independence members through our Direct Ship Drug Program.

Over the next few months, we will publish additional Partners in Health Update^SM articles to provide information like:

• the complete list of recommendations for Synagis from the American Academy of Pediatrics
• information about how to order Synagis through our Direct Ship Drug Program

New order forms branded with the PerformSpecialty logo and contact information will be available on our Direct Ship Drug Program website in advance of the RSV season. Providers should discard previous copies of the Synagis Direct Ship order forms, as these versions will no longer be accepted by Independence.

Later this month, we will send a letter to providers who have a history of prescribing Synagis to Independence members with more details about this change.

Learn more

Providers can find additional information about Synagis in the Independence Medical Policy #08.00.22m: Immune Prophylaxis for Respiratory Syncytial Virus (RSV). To view this policy, visit our Medical Policy Portal.

If you have questions about the Synagis distribution program, please call Customer Service at 1-800-ASK-BLUE.